We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BAMI:MILBanco BPM SpA Analysis

Data as of 2026-03-10 - not real-time

€11.72

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Banco BPM trades at €11.72, well below its 20‑day (≈€12.20) and 50‑day (≈€12.53) simple moving averages and also under the 200‑day SMA (≈€11.87), indicating a short‑term price weakness. The RSI of 41.7 and a bearish MACD histogram reinforce the technical downside, while the stock sits just above the identified support at €10.94, leaving limited downside cushion. On the valuation side, the trailing P/E of 8.5 is less than half the industry average of 17.3, and the price‑to‑book of 1.14 suggests the market is pricing the bank close to its net asset value. A dividend yield of 8.8% with a payout ratio of 76% makes the stock attractive for income‑focused investors, and analysts’ price targets (~€13.5) imply roughly 16% upside. Fundamentally, operating margins remain strong at 43% and ROE is healthy at 14%, but revenue has contracted 10.5% YoY, and net cash is negative after accounting for €30.4 bn of debt.
Recent news points to a positive governance shift, with minority shareholders gaining double the board seats, and analyst revisions that are reframing the investment story, both of which could bolster confidence. However, the bank’s 30‑day volatility of 35% and a max drawdown near 22% signal heightened price swings, while Italy’s macro‑economic environment adds medium‑level geographic and regulatory risk. Overall, the stock appears undervalued with solid dividend income, but investors should weigh the earnings slowdown and elevated volatility.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bearish momentum
  • High dividend yield providing immediate return
  • Elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation discount vs peers (low P/E)
  • Analyst price targets indicating ~16% upside
  • Improved governance and positive analyst sentiment

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustainable dividend yield and solid ROE
  • Stable earnings margins despite revenue dip
  • Undervalued balance‑sheet metrics relative to industry

Key Metrics & Analysis

Financial Health

Revenue Growth-10.50%
Profit Margin37.42%
P/E Ratio8.5
ROE13.93%
ROA1.04%
P/B Ratio1.1
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI41.7
Support€10.94
Resistance€13.06
MA 20€12.20
MA 50€12.54
MA 200€11.87
MACDBearish
VolumeStable
Fear & Greed Index76.91

Valuation

Target Price€13.65
Upside/Downside16.47%
GradeUndervalued
TypeValue
Dividend Yield8.80%

Risk Assessment

Beta0.60
Volatility35.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.